Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patients

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 9, 2013, Pages 1849-1857

  Steinmetz, Tilman ^a   Kuhr, Kathrin ^b   Totzke, Uwe ^c   Hellmich, Martin ^b   Heinz, Melanie ^d   Neise, Michael ^e   Mittermüller, Johann ^f   Tessen, Hans Werner ^g   Reiser, Marcel ^h   Severin, Kai ^d   Schmitz, Stephan ^d  

^a Hämatologie und Onkologie ^*  (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Totzke and Dreher Scientific SA   (Switzerland)

^d Outpatient Clinic for Hematology and Oncology   (Germany)

^e Oncologic Outpatient Clinics   (Germany)

^f Outpatient Clinic for Hematology and Oncology   (Germany)

^g Outpatient Clinic for Hematology and Oncology   (Germany)

^h Outpatient Clinic for Oncology and Haematology   (Germany)

Author keywords

Anemia; Diagnostics; Erythropoietin; Intravenous iron; Predictor

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SOLUBLE TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NEOPLASM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; SEX DIFFERENCE; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84888114027     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0104     Document Type: Article

References (46)

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40: 2293-306. (Pubitemid 39348881)
2. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16: 3412-25. (Pubitemid 28481641)
3. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19: 2865-74. (Pubitemid 32538196)
4. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23: 2606-17. (Pubitemid 46179449)
5. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168: 2377-81.
6. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist 2011;16(Suppl 3): 12-8.
7. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373: 1532-42.
8. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011;17: 6373-80.
9. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3): 33-6.
10. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102: 301-15.
11. Marchal C, Misset JL, Casadevall N, Marec-Berard P, Chastagner P, Kassab-Chahmi D, et al. [Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]. Cancer Radiother 2008;12: 126-33.
12. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28: 4996-5010.
13. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26: 132-49.
14. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22: 1301-7. (Pubitemid 41079845)
15. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12: 231-42.
16. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26: 1611-8.
17. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26: 1619-25.
18. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85: 655-63.
19. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21: 627-32. (Pubitemid 46444544)
20. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapyassociated anemia. J Clin Oncol 2011;29: 97-105.
21. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012;23: 1954-62.
22. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105: 199-204. (Pubitemid 46441460)
23. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116: 522-5.
24. Steinmetz HT, Tsamaloukas A, Schmitz S, Wiegand J, Rohrberg R, Eggert J, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010;19: 261-9.
25. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24: 475-82.
26. Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 2012;3: 177-91.
27. Katodritou E, Zervas K, Terpos E, Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol 2008;142: 3-10. (Pubitemid 351783159)
28. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43: 258-70. (Pubitemid 46127840)
29. Mikhael J, Melosky B, Cripps C, Rayson D, Kouroukis CT. Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol 2007;14: 209-17.
30. NCCN. Practice guidelines in oncology: cancer and chemotherapy-induced anemia. Available from: http://www. nccn.org/professionals/physician-gls/pdf/ anemia.pdf. (a) accessed March 2007, (b) Version 1. 2013, accessed March 2013.
31. Steinmetz T, Hellmich M, Neise M, Aldaud A, Lerchenmuller C, Tsamaloukas A, et al. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 2007;12: 748-55. (Pubitemid 47036209)
32. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122: 386-93. (Pubitemid 36951622)
33. Kolesar JM, Duren BA, Baranski BG. Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders. J Oncol Pharmacy Practice 2004;10: 1-6. (Pubitemid 38344491)
34. Steinmetz T, Totzke U, Soling U, Groschek M, Mittermuller J, Schweigert M, et al. Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia - examination of practice in Germany. Curr Med Res Opin 2008;24: 2751-6.
35. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89: 1052-7. (Pubitemid 27121300)
36. Lee EJ, Oh EJ, Park YJ, Lee HK, Kim BK. Soluble transferrin receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation. Clin Chem 2002;48: 1118-21.
37. Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif 2012;33: 238-44.
38. Ganz T, Nemeth E. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med 2012;2:a011668.
39. Thomas C, Kobold U, Thomas L. Serum hepcidin-25 in comparison to biochemical markers and hematological indices for the differentiation of iron-restricted erythropoiesis. Clin Chem Lab Med 2011;49: 207-13.
40. Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, Migliore A, et al. High serum levels of TNF-alpha and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. Ann Oncol 2010;21: 1523-8.
41. Ukarma L, Johannes H, Beyer U, Zaug M, Osterwalder B, Scherhag A. Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin Chem 2009;55: 1354-60.
42. den Elzen WP, de Craen AJ, Wiegerinck ET, Westendorp RG, Swinkels DW, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica 2013;98: 448-54.
43. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14: 3262-7.
44. Hofmann A, Farmer S, Shandere A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 2011;16: 3-11.
45. Thomson A, Farmer S, Hofmann A, Isbister J, Shander A. Patient blood management - a new paradigm for transfusion medicine? ISBT Science Series 2009;4: 423-35.
46. Ray-Coquard I, Dussart S, Goillot C, Mayeur D, Debourdeau P, Ghesquieres H, et al. A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group. Ann Oncol 2009;20: 1105-12.